RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn’s Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

by | Mar 12, 2025 | Clinical Trials | 0 comments

​ 

The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in Crohn’s Disease (CD) patients who are all MAP-positive, and will…

 The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in Crohn’s Disease (CD) patients who are all MAP-positive, and will… 

Submit a Comment

Your email address will not be published. Required fields are marked *